Skip to Content
Merck
All Photos(1)

Key Documents

T0318

Sigma-Aldrich

Tranilast

≥98% (HPLC), powder

Synonym(s):

2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]amino] benzoic acid, 3,4-DAA, N-(3,4-Dimethoxycinnamoyl)anthranilic acid, Rizaben, SB-252218

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C18H17NO5
CAS Number:
Molecular Weight:
327.33
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

color

white to beige

mp

166.2-168.2 °C (lit.)

solubility

DMSO: >10 mg/mL
H2O: insoluble

originator

Kissei

storage temp.

2-8°C

SMILES string

COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC

InChI

1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+

InChI key

NZHGWWWHIYHZNX-CSKARUKUSA-N

Gene Information

Application

The effect of Tranilast on mast cell surface receptors was studied in murine bone marrow-derived mast cells.

Biochem/physiol Actions

Tranilast also inhibits vascular smooth muscle cell proliferation by inhibiting the cyclin-dependent kinase inhibitor-1(p21Waf1/Cip1) and may be useful in treating cardiac allograft vasculopathy. It is used in treating hypertrophic scars and keloids. Tranilast inhibits tumor necrosis factor (TNF-α and TGF-β2), obstructing epithelial-mesenchymal transition in human retinal pigment epithelial cell line (ARPE).
Tranilast is an anti-asthma drug, which inhibits LTC4 and PGE2 formation in stimulated monocytes, but does not inhibit cyclooxygenase or lipoxygenase activity; inhibits mast cell degranulation; inhibits VEGF-induced angiogenesis in vivo and also inhibits proliferation and tube formation of human endothelial cells in vitro. Tranilast may represent a new class of drugs for therapy to treat ongoing TH1-mediated autoimmune diseases.

Features and Benefits

This compound was developed by Kissei. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Tranilast inhibits cardiac allograft vasculopathy in association with p21waf1/cip1 expression on neointimal cells in murine cardiac transplantation model
Izawa A, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology, 21(7), 1172-1178 (2001)
Henrik Brovold et al.
Scientific reports, 9(1), 10513-10513 (2019-07-22)
Several epidemiological studies have pointed at serum uric acid (SUA) as an independent risk factor for mortality, diabetes, hypertension, cardiovascular and kidney disease; however, no clear pathogenic pathway is established. Uric acid (UA) crystals show pro-inflammatory properties and can thus
Philippe Lachapelle et al.
Pharmacology & therapeutics, 187, 98-113 (2018-02-21)
The transforming growth factor (TGF)-β cytokines play a central role in development and progression of chronic respiratory diseases. TGF-β overexpression in chronic inflammation, remodeling, fibrotic process and susceptibility to viral infection is established in the most prevalent chronic respiratory diseases
Yosuke Nakatani et al.
Journal of the American College of Cardiology, 61(5), 582-588 (2013-01-01)
This study sought to assess the effects of tranilast on atrial remodeling in a canine atrial fibrillation (AF) model. Tranilast inhibits transforming growth factor (TGF)-β1 and prevents fibrosis in many pathophysiological settings. However, the effects of tranilast on atrial remodeling
Kaname Uno et al.
Journal of clinical gastroenterology, 46(9), e76-e82 (2012-09-08)
As circumferential or near-circumferential endoscopic submucosal dissection (ESD) for superficial esophageal neoplasms might evoke refractory strictures, multiple sessions of endoscopic balloon dilation (EBD) are required. We aimed to assess the effectiveness and safety of oral agent tranilast with EBD for

Related Content

Discover Bioactive Small Molecules for Lipid Signaling Research

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service